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ABSTRACT
Cytochrome P450 2A6 (CYP2A6) encodes the enzyme responsible for the majority of nicotine metabolism. Previous
studies support that slow metabolizers smoke fewer cigarettes once nicotine dependent but provide conﬂicting results
on the role of CYP2A6 in the development of dependence. By focusing on the critical period of young adulthood, this
study examines the relationship of CYP2A6 variation and smoking milestones. A total of 1209 European American
young adults enrolled in the Collaborative Study on the Genetics of Alcoholism were genotyped for CYP2A6 variants
to calculate a previously well-validated metric that estimates nicotine metabolism. This metric was not associated with
the transition from never smoking to smoking initiation nor with the transition from initiation to daily smoking
(P>0.4). But among young adults who had become daily smokers (n=506), decreased metabolism was associated
with increased risk of nicotine dependence (P=0.03) (deﬁned as Fagerström Test for Nicotine Dependence score
≥4). This ﬁnding was replicated in the Collaborative Genetic Study of Nicotine Dependence with 335 young adult daily
smokers (P=0.02). Secondary meta-analysis indicated that slow metabolizers had a 53 percent increased odds
(OR=1.53, 95 percent CI 1.11–2.11, P=0.009) of developing nicotine dependence compared with normal
metabolizers. Furthermore, secondary analyses examining four-level response of time to ﬁrst cigarette after waking
(>60, 31–60, 6–30, ≤5minutes) demonstrated a robust effect of the metabolism metric in Collaborative Study on
the Genetics of Alcoholism (P=0.03) and Collaborative Genetic Study of Nicotine Dependence (P=0.004), illustrating
the important role of this measure of dependence. These ﬁndings highlight the complex role of CYP2A6 variation
across different developmental stages of smoking behaviors.
Keywords CYP2A6, genetics, nicotine dependence, smoking, young adults.
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INTRODUCTION
The development of nicotine dependence requires
smoking initiation, conversion from experimental to daily
use and ﬁnally the development of advanced smoking
behaviors (Belsky et al., 2013; Bierut, 2011). Although
the majority of adult smokers initiate smoking during
adolescence, rates of daily smoking substantially increase
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during young adulthood (1 percent at ages 12–17, 12
percent at ages 18–25, 14 percent at ages 26 or more)
(NSDUH, 2015). Furthermore, among those who report
current daily smoking, the proportion of individuals
who smoke a pack or more a day also dramatically
increases with age (12 percent at ages 12–17, 23 percent
at ages 18–25 and 33 percent at ages 26 or more)
(NSDUH, 2015). Increasing our knowledge of what
factors drive some young adults and not others to transi-
tion from initiation to daily smoking and then to
advanced smoking behaviors is important for effectively
preventing the progression toward nicotine dependence.
One genetic factor that plays an important role in the
development of smoking behaviors is variation in the
gene Cytochrome P450 2A6 (CYP2A6), which encodes
the cytochrome P450 enzyme responsible for the major-
ity of oxidation of nicotine to cotinine; this is the primary
pathway of nicotine metabolism in humans (Hukkanen
et al., 2005). The CYP2A6 locus is highly polymorphic,
and alleles with reduced function have been associated
with slower rates of nicotine metabolism. Common vari-
ants deﬁne multiple CYP2A6 haplotypes in individuals
of European ancestry (Haberl et al., 2005), and the
majority of inter-individual variation in the metabolism
of nicotine to cotinine is explained by CYP2A6 genotypes
in European Americans (Bloom et al., 2011).
The region on chromosome 19 encompassing
CYP2A6 is genome-wide signiﬁcantly associated with
cigarettes per day in large meta-analyses of European
ancestry adults (TAG, 2010; Thorgeirsson et al., 2010).
Among nicotine dependent adults, several studies
demonstrate that slower metabolizers smoke fewer
cigarettes per day (Benowitz, 2008; Malaiyandi et al.,
2005). This observation is thought to reﬂect that
smokers naturally titrate cigarette consumption to main-
tain steady nicotine levels.
Studies in youth present conﬂicting results regarding
the effect of nicotine metabolism on the development of
nicotine dependence and other smoking behaviors
(Audrain-McGovern et al., 2007; Cannon et al., 2016;
Chenoweth et al., 2016; Huang et al., 2005; Moolchan
et al., 2009; O’Loughlin et al., 2004; Rubinstein et al.,
2008; Rubinstein et al., 2013). Some studies suggest that
slow nicotine metabolism is associated with an increased
risk of nicotine dependence (Chenoweth et al., 2016;
O’Loughlin et al., 2004; Rubinstein et al., 2013), possibly
reﬂecting an increased sensitivity to initial nicotine expo-
sure among youth who metabolize nicotine more slowly.
In contrast, other studies suggest that slower
metabolizers have a decreased risk for dependence and
related symptoms (Audrain-McGovern et al., 2007;
Rubinstein et al., 2008), paralleling ﬁndings in adults
regarding reduced heaviness of smoking among slow
metabolizers.
Our goal was to investigate the ways in which varia-
tion in CYP2A6 relates to the development of smoking
behaviors during the critical period of young adulthood
in a sample of European Americans. A better understand-
ing of how variation in nicotine metabolism contributes
to the acquisition of smoking milestones will add to our
fundamental knowledge of the developmental processes
that lead to nicotine dependence and has the potential
to identify individuals at increased susceptibility during
this critical period.
MATERIALS AND METHODS
Primary sample description
The Collaborative Study on the Genetics of Alcoholism
(COGA) is a United States multi-center, family study that
aims to identify genes that contribute to alcohol use dis-
orders and related phenotypes (Begleiter et al., 1995).
Since 2005, the adolescent and young adult study in
COGA has used a longitudinal design to examine the
development of substance use disorders in youth from
high-risk (deﬁned as recruited through alcohol depen-
dent probands with multiple affected family members)
and community comparison families. Members aged
12–22 years were recruited from six sites across the
United States and interviewed approximately every
2 years with ongoing data collection. Detailed descrip-
tions of the COGA prospective adolescent and young
adult sample have been previously published (Chorlian
et al., 2015; Dick et al., 2013).
Smoking behaviors in COGA
Assessments were performed using the Semi-Structured
Assessment for the Genetics of Alcoholism (SSAGA),
which gathers detailed information on substance use
with high reliability and validity (Bucholz et al., 1994;
Bucholz et al., 1995; Hesselbrock et al., 1999). Smoking
initiation was evaluated with the question ‘Have you ever
smoked a full cigarette?’ Daily smoking was deﬁned as
smoking at least 4 days per week for at least a month as
performed in previous analyses (Kapoor et al., 2012). This
was assessed among individuals who had initiated
smoking using the questions ‘When you were smoking
regularly, how many days per week did you usually
smoke cigarettes?’ and ‘For how long did you smoke this
many cigarettes at that rate?’
Among individuals who reported daily smoking
(n=506), several measures of more advanced smoking
behaviors were examined in this analysis that focused
on the period of heaviest smoking. Time to ﬁrst cigarette
after waking was derived from the question ‘During this
period when you were smoking the most, about how
many minutes after you woke up did you smoke your ﬁrst
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cigarette?’ and the four response options are the follow-
ing: more than 1hour, 31–60minutes, 6–30minutes
and within 5minutes. For the analyses, time to ﬁrst
cigarette was dichotomized into >5minutes (n=338,
67 percent) and ≤5minutes after waking (n=168, 33
percent). Cigarettes per day was evaluated with the ques-
tion ‘During the period of time when you were smoking
the most, about how many cigarettes did you usually
have per day?’ and the four response options are as
follows: 10 or fewer, 11–20, 21–30 and 31 or more
cigarettes. Cigarettes per day was dichotomized into ≤20
(n=367, 74 percent) and >20 cigarettes (n=131, 26
percent) in the analyses as performed in previous studies
(Belsky et al., 2013; Broms et al., 2006). A total
Fagerström Test for Nicotine Dependence (FTND) score
during the heaviest period of smoking was calculated at
each interview using responses to these two questions
as well as responses to questions assessing the four
remaining criteria (Heatherton et al., 1991). For the
analyses, nicotine dependence was deﬁned as a FTND
score of four or more (n=306, 61 percent), which is a
sensitive and speciﬁc cut-off for smoking biomarkers
(Huang et al., 2008) and has been used in previous
genetic studies (Bierut et al., 2007; Saccone et al., 2009).
Given the longitudinal design of this study, an
endorsement of smoking initiation or daily smoking at
any interview at age 30 years or younger was used to
capture these behaviors during young adulthood. The
highest FTND score across available interviews at age
30 years or younger was chosen to capture the lifetime
maximum, and time to ﬁrst cigarette as well as cigarettes
per day were set at these interviews.
Genotyping
Bloom et al. (2011) developed a metric based on several ge-
netic variants in CYP2A6 to estimate nicotine metabolism.
Cross-validation estimates that this metric predicts approx-
imately 70 percent of the variance in metabolism of orally
administered nicotine to cotinine in European Americans
(Bloom et al., 2012). Our goal was to use this CYP2A6
metabolism metric to test whether CYP2A6 variation
predicts cigarette smoking behaviors in young adulthood.
Five CYP2A6 single nucleotide polymorphisms (SNPs)
(rs1801272, rs28399442, rs28399433, rs1137115 and
rs28399435) were genotyped using the LGC (Teddington,
Middlesex, UK) genomics competitive allele-speciﬁc poly-
merase chain reaction (KASP) (lgcgenomics.com). The
CYP2A6 copy number variant (CNV) was genotyped with
TaqMan 5’ Nuclease Assays (Life Technologies, Thermo
Fisher Scientiﬁc, Waltham, MA, USA). The CNV assay
was run in duplicate, and genotype calls were made using
CopyCaller (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
software. The program PEDCHECK (O’Connell and Weeks,
1998) was used to examine Mendelian inheritance, and
only individuals with no Mendelian inconsistencies were
included in the analyzed sample. The metabolism metric
was calculated based on the genotypes of the ﬁve CYP2A6
SNPs and the CNVusing an algorithmdescribed in Table S1
(adapted from Bloom et al., 2012).
A set of 64 ancestry informative markers was geno-
typed as part of a 96 SNP Biorepository Panel by the
Rutgers University Cell and DNA Repository. These
markers were used in SNPrelate, a function in R, to assign
ancestry groups. HapMap populations were included as
reference groups. There was high concordance (98
percent) between self-reported and genetically determined
ancestry among European Americans. Only individuals
with a genetic ancestry of European American were
included in the analysis because the metric was optimized
for this population (Bloom et al., 2011).
Primary sample selection
The analysis was restricted to individuals who had
reached young adulthood (19 years or older) because
we were interested in transitions to daily smoking and
advanced smoking behaviors, outcomes that often occur
during this time. In the COGA adolescent and young
adult study, 1209 European ancestry individuals with a
last interview age of 19 years or older were genotyped
for the CYP2A6 variants, and participants for the analy-
ses were drawn from this group (Fig. 1). The sample used
to analyze daily versus non-daily smokers consisted of
776 individuals who had initiated smoking (64 percent
of all subjects). For transitions to advanced smoking
behaviors, we focused on the sample of 506 daily smokers
(65 percent of initiators, 42 percent of all subjects,
described in Table 1).
Figure 1 Primary Collaborative Study on the Genetics of Alcohol-
ism (COGA) sample selection. CYP2A6, Cytochrome P450 2A6;
FTND, Fagerström Test for Nicotine Dependence
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Replication COGEND sample
The Collaborative Genetic Study of Nicotine Dependence
(COGEND) is a multi-center case-control study designed
to identify genes that contribute to nicotine dependence
(Saccone et al., 2007). Community based recruitment
enrolled participants ages 25–45 years old. Cases were
required to be current smokers and have an FTND score
of four or more. Controls were required to have smoked
at least 100 cigarettes and have a lifetime maximum
FTND score of zero or one. For this analysis, only subjects
who self-reported as being of European ancestry were
examined (previous analyses using EIGENSTRAT have
shown a high correspondence with genetic ancestry
groups; Saccone et al., 2009). Genotyping of variants to
calculate the metabolism metric in COGEND has been
previously described (Bloom et al., 2012). We focused
on the subsample of 377 COGEND young adults ages
25–30 that overlapped with the ages of the primary
COGA sample. From this group, 335 (89 percent)
reported smoking every day or nearly every day for at
least 2months and were considered daily smokers.
Replication sample characteristics of these daily smokers
are described in Table 1.
Primary data analysis
Data were analyzed using the Statistical Analysis System.
Logistic regression was used to model dichotomous out-
comes of smoking initiation, daily smoking, nicotine
Table 1 Characteristics of primary and replication samples of European American young adults.
Characteristic COGA young adult European American
daily smokers (n=506)
Replication: COGEND young adult European
American daily smokers (n= 335)
Sex, n (percent) – –
Males 288 (57 percent) 129 (39 percent)
Females 218 (43 percent) 206 (61 percent)
Age at last interview examined, years – –
Mean sd 24.4 3.3 27.8 1.7
Range 19–30 25–30
No. of interviews examined – –
Mean sd 4.0 1.4 –
Range 1–6 1
Family status, n (percent) – –
From high-risk families 464 (92 percent) –
From comparison families 42 (8 percent) –
Lifetime DSM-IV alcohol dependence, n (percent) 185 (37 percent) 35 (11 percent)
No. of extended families 310 –
No. of nuclear families (full siblings) 431 –
FTND score – –
Mean sd 4.2 2.6 3.0 3.3
Range 0–10 0–10
Nicotine dependence (FTND ≥ 4), n (percent) 306 (60 percent) 166 (50 percent)
Time to ﬁrst cigarette after waking – –
More than 1 hour 80 (16 percent) 168 (50 percent)
31–60minutes 73 (14 percent) 19 (6 percent)
6–30minutes 185 (37 percent) 67 (20 percent)
Within 5minutes 168 (33 percent) 81 (24 percent)
Cigarettes per day – –
10 or fewer 182 (36 percent) 171 (51 percent)
11–20 185 (37 percent) 78 (23 percent)
21–30 81 (16 percent) 45 (13 percent)
31 or more 50 (10 percent) 41 (12 percent)
Metabolism metric* – –
Mean sd 0.86 0.07 0.86 0.07
Range 0.44–0.90 0.44–0.90
Metabolism status – –
Low (Metric ≤ .85) 134 (26 percent) 103 (31 percent)
Normal (Metric> .85) 372 (74 percent) 232 (69 percent)
*Distribution of metabolism metric in COGA and COGEND young adult daily smokers provided in Fig. S1. COGA, Collaborative Study on the Genetics of
Alcoholism; COGEND, Collaborative Genetic Study of Nicotine Dependence; FTND, Fagerström Test for Nicotine Dependence.
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dependence, time to ﬁrst cigarette and cigarettes per day.
In the primary analyses in COGA and COGEND, the
continuous metabolism metric, sex, study site and last in-
terviewagewere included as predictor variables. In COGA,
family structure was accounted for using generalized
estimating equations via PROC GENMOD. Results from
the COGEND replication sample were meta-analyzed
with the primary COGA results (Table 2) using a
publically available Statistical Analysis System macro
(>http://www.hsph.harvard.edu/donna-spiegelman/soft-
ware/metaanal/). Meta-analyses results were based on
ﬁxed effect models to determine the evidence for
association within the collected samples. In these analy-
ses, we did not observe heterogeneity between the two
studies based on the Q statistic (P>0.1).
Secondary data analyses
Secondary analyses were performed to further explore
our primary ﬁndings. First, individuals were divided into
slow and normal metabolizers using a cut-off of ≤0.85
on the metabolism metric as previously described (Chen
et al., 2014). This cut-off captures the lowest quartile of
metabolizers, and this dichotomous variable was used in
logistic regression models of smoking behaviors. Second,
because the majority of the COGA sample was recruited
from families at high-risk for alcoholism, the primary
analyses examining the continuous metabolism metric
and smoking milestones were repeated with the covariate
of lifetime DSM-IV alcoholism dependence. Third, after
observing an association between the metabolism metric
and the time to ﬁrst cigarette dichotomous variable (>5
and ≤5minutes), the four-level variable of time to ﬁrst
cigarette after waking (>60, 31–60, 6–30, ≤5minutes)
was also investigated in cumulative logistic regression
models. These analyses were performed to assess whether
the continuous metabolism metric predicted response
across the four ordinal categories.
Ethics statement
Institutional review boards at all COGA and COGEND
sites approved the study design and the studies were car-
ried out in accordance with the Declaration of Helsinki.
Written consent was received from all study participants.
RESULTS
Participant characteristics
Demographic, behavioral and metabolism metric charac-
teristics of the COGA and COGEND samples are presented
in Table 1. The primary COGA sample of young adult
daily smokers consisted of 506 European American indi-
viduals from 431 nuclear families from 310 extended
families. The mean age at last interview was 24 years,
43 percent were female, and 92 percent came from
families at high-risk for alcoholism, with 37 percent
meeting the criteria for lifetime DSM-IV alcohol depen-
dence. Among these daily smokers, 61 percent were
nicotine dependent, 33 percent smoked within 5minutes
after waking and 26 percent smoked greater than 20
cigarettes per day (Fig. 1 and Table 1). A total of 26
percent of the young adults were slow metabolizers, and
the distribution of the metabolism metric (Fig. S1) was
similar to that seen in other samples (Bloom et al.,
2012; Chen et al., 2014).
The COGEND replication sample of young adult daily
smokers consisted of 335 European Americans with an
Table 2 Logistic regression models examining the association of a continuous CYP2A6metabolism metric and smoking milestones in
young adults.
Metabolism Metric in COGA
young adults
Replication: metabolism metric in
COGEND young adults
Meta-analysis of
results
Beta SE P-value Beta SE P-value Beta SE P-value
Among all young adults
(COGA n= 1209)
– – – – – – – – –
Smoking initiation 0.46 0.97 0.63 – – – – – –
Among young adult ever-smokers
(COGA n= 776)
– – – – – – – – –
Daily smoking 0.92 1.16 0.42 – – – – – –
Among young adult daily smokers
(COGA n= 506; COGEND n=335)
– – – – – – – – –
Nicotine dependence 3.49 1.62 0.03 4.36 1.86 0.02 3.86 1.21 0.002
Smoked ﬁve or fewer minutes after waking 2.44 1.34 0.07 4.63 1.82 0.01 3.21 1.07 0.003
Smoked more than 20 cigarettes per day 1.10 1.59 0.49 1.53 1.85 0.41 0.01 1.17 0.99
All models include sex, study site and age of last interview as covariates. Analyses with Collaborative Study on the Genetics of Alcoholism (COGA) were
also adjusted for familial clustering.
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average age at interview of 28 years and the majority
were female (61 percent). Among COGEND young adult
daily smokers, 50 percent were nicotine dependent, 24
percent smoked within 5minutes after waking, 25 per-
cent smoked greater than 20 cigarettes per day and 31
percent were slow metabolizers (distribution in Fig. S1).
CYP2A6 metabolism metric and early smoking behaviors
The continuous CYP2A6 metabolism metric was not
associated with smoking initiation (P=0.63) nor with
the development of daily smoking (P=0.42) in the COGA
young adults (Table 2). Of the 270 young adults who
initiated smoking but did not transition to daily smoking,
essentially all of them (98 percent) failed to develop any of
the more advanced smoking behaviors, including nico-
tine dependence and smoking within 5minutes after
waking. This supports the notion that daily smoking is
a prerequisite for the development of advanced smoking
behaviors. Therefore, subsequent analyses of advanced
smoking milestones focused on the 506 daily smokers.
CYP2A6 metabolism metric and advanced smoking
behaviors in daily smokers
The CYP2A6 haplotypes predictive of slower metabolism
were associated with an increased risk of nicotine depen-
dence in both the primary COGA and replication
COGEND samples of young adult daily smokers (Table 2,
Fig. 2). In multivariate models adjusting for age, sex
and study site, the continuous CYP2A6 metabolism
metric had a signiﬁcant effect in COGA (P=0.03) and
COGEND (P=0.02), where a slow predicted metabolism
was associated with an increased risk of nicotine depen-
dence deﬁned by an FTND score ≥4 (Table 2). Secondary
analyses showed that slow metabolizers (deﬁned by a
metric of ≤0.85) had a 53 percent increased odds
(OR=1.53, 95 percent CI 1.11–2.11, P=0.009) of
developing nicotine dependence as compared with nor-
mal metabolizers (metric>0.85) in meta-analyses of
COGA and COGEND studies (Table S2). Figure 2 illus-
trates this association by showing that a larger propor-
tion of slow metabolizers in both COGA and COGEND
developed nicotine dependence as compared with normal
metabolizers.
Consistent with the nicotine dependence results, a
lower metabolism metric was associated with an in-
creased risk of smoking within 5minutes after waking
(Table 2, Fig. 2). The continuous CYP2A6 metabolism
metric had a trending effect in COGA (P=0.07) and a
signiﬁcant effect in COGEND (P=0.01). In secondary
meta-analysis, slow metabolizers had a 57 percent
increased odds (OR=1.57, 95 percent CI 1.13–2.18,
P=0.007) of smoking within 5minutes after waking
compared with normal metabolizers (Table S2). The
CYP2A6 metabolism metric was not associated with
smoking more than 20 cigarettes per day in either sample
or meta-analysis (Table 2, Fig. 2). Secondary analyses
examining the effect of the metabolism metric on
smoking behaviors after controlling for DSM-IV alcohol
dependence illustrates similar results (Table S3),
supporting that the associations are not dependent on al-
coholism status.
Robustness of effect of CYP2A6 metabolism metric on
time to ﬁrst cigarette after waking
Secondary analyses using all four responses of time to
ﬁrst cigarette after waking (>60, 31–60, 6–30, ≤5 -
minutes) demonstrated a more robust effect of the metab-
olism metric in both COGA (P=0.03) and COGEND
(P=0.004) as compared with the dichotomous time to
ﬁrst cigarette (>5 and ≤5minutes) used in our primary
analysis (Table S4 and Table 2, respectively). Figure S2
illustrates that across the four categories, there was an
increased proportion of slow metabolizers at shorter
times to ﬁrst cigarette after waking among COGA daily
smokers. In COGEND daily smokers, we observed a simi-
lar trend, except in the category of 31–60minutes that
only had 19 individuals (6 percent of sample, Table 1).
Figure 2 Association between predicted metabolism and smoking behaviors in two studies of European American young adult daily smokers.
Error bars reﬂect standard errors adjusted for sample size. COGA, Collaborative Study on the Genetics of Alcoholism; COGEND, Collaborative
Genetic Study of Nicotine Dependence
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Taken together, these results support a possible ‘dosage
effect’ where predicted slower metabolism was correlated
with smoking sooner after waking.
DISCUSSION
Young adulthood is a critical developmental period for
the progression from initiation to more advanced
smoking milestones (NSDUH, 2015). This study links
variation in a genome-wide signiﬁcant gene, CYP2A6,
with the development of smoking behaviors in two inde-
pendent samples of European American young adults.
Using speciﬁc CYP2A6 polymorphisms, we calculated a
nicotine metabolism metric, which has been previously
shown to account for approximately 70 percent of the
variance in metabolism of orally administered nicotine
to cotinine in European Americans (Bloom et al., 2012;
Bloom et al., 2011). Our primary ﬁnding is that slower
nicotine metabolism is associated with an elevated risk
of developing nicotine dependence among young adult
daily smokers, adding important insight into the role of
variation in CYP2A6 across stages of smoking develop-
ment, as illustrated in Fig. 3.
Despite having an important role in the development
of nicotine dependence among daily smokers, variation
in CYP2A6 was not associated with smoking initiation
nor the progression to daily smoking (step 1 in Fig. 3).
Previous twin studies support that environmental inﬂu-
ences primarily drive early adolescent nicotine use, and
that the role of heritable factors on smoking behaviors
increases throughout young adulthood (Kendler et al.,
2008; Koopmans et al., 1999). Our results are consistent
with this model by providing evidence of a speciﬁc gene
that impacts the transition from daily smoking to
nicotine dependence, without inﬂuencing initiation and
daily smoking.
The observation that decreased predicted nicotine
metabolism is associated with increased risk of nicotine
dependence in young adult daily smokers also builds on
previous studies conducted in adolescents (step 2 in
Fig. 3). O’Loughlin et al. (2004) followed 228 non-
dependent smokers in grade seven over approximately
30months and found that individuals with less active
genetic variants in CYP2A6 were more likely to develop
nicotine dependence but smoked fewer cigarettes per
day once dependent. In a follow-up study examining
421 adolescents who had ever smoked a cigarette,
Chenoweth et al. (2016) similarly found that slow metab-
olism conferred by CYP2A6 variation was associated
with increased risk of nicotine dependence in adoles-
cence. Huang et al. (2005) examined variation in
CYP2A6 in 1518 adolescents enrolled in a longitudinal
study in the United Kingdom and similarly found that
individuals with variants associated with slower metabo-
lism were more likely to be current versus former
smokers at age 18 years compared with normal
metabolizers. Rubinstein et al. (2013) assessed a
biomarker of the rate of nicotine metabolism (the nicotine
metabolite ratio) in 164 adolescent smokers and found
that slower metabolizers showed greater symptoms of
Figure 3 A theoretical framework of the development of smoking behaviors in relation to CYP2A6, Cytochrome P450 2A6 (CYP2A6) var-
iation. Steps 1 and 2 are supported by this paper and previous studies. Steps 3 and 4 are supported by previous studies (reviewed in Benowitz,
2008; Malaiyandi et al., 2005)
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dependence. Our ﬁndings in two independent samples
expand on these earlier results by demonstrating that
during early young adulthood, when many advanced
smoking behaviors develop, slow metabolizers who
smoke daily continue to have a greater risk of lifetime
dependence.
The increased susceptibility to developing nicotine
dependence encountered by youth who are slow
metabolizers compared with normal metabolizers has
been hypothesized to reﬂect prolonged exposure to nico-
tine because of its longer half-life during initial smoking
experiences (Chenoweth et al., 2013; Malaiyandi et al.,
2005; Rubinstein et al., 2013). Although accumulating
evidence supports this role, it is important to note that
a few studies show the opposite effect where slow metab-
olism is associated with decreased risk of smoking behav-
iors in youth (Audrain-McGovern et al., 2007; Moolchan
et al., 2009; Rubinstein et al., 2008). For example,
Audrain-McGovern (2007) examined 222 adolescent
ever-smokers of European ancestry and found that
normal CYP2A6 metabolizers developed symptoms of
dependence at a faster rate than slower CYP2A6
metabolizers. Other studies suggest that the increased
risk of slower metabolizers for developing nicotine depen-
dence in adolescence disappears by young adulthood
(Chenoweth et al., 2016). Cannon et al. (2016) followed
296 participants across ages 16–24 years and found that
using a CYP2A6 diplotype predictive metric, intermediate
metabolism compared with slow and normal was a risk
factor for smoking frequency and nicotine dependence.
By the end of the study at age 24 years, however, the
individuals with predicted normal metabolism were at
greatest risk for these smoking behaviors. Many possible
explanations exist for these discrepant results. One
hypothesis is that the effect of slower nicotine metabolism
transitions rapidly from increasing risk to being protec-
tive (Cannon et al., 2016 O’Loughlin et al., 2004), and
previous studies may have observed different develop-
mental periods in the fast-changing early course of
smoking behaviors. The ascertainment of subjects and
baseline smoking behaviors also varies across studies,
which may inﬂuence the power to detect associations.
Furthermore, previous studies use different measures of
smoking behaviors and nicotine dependence, and it is
possible that they capture different components of depen-
dence that are differentially inﬂuenced by CYP2A6
metabolism.
Our results suggest that time to ﬁrst cigarette after
waking is a critical contributor to the association
between the CYP2A6 metabolism metric and develop-
ment of nicotine dependence assessed by the FTND
criteria among daily smokers. Little consensus exists on
the best measure of nicotine dependence, but research
supports that two items from the FTND score, time to ﬁrst
cigarette after waking and cigarettes smoked per day, are
strong, valid, reliable predictors of quitting behaviors,
which are key indicators of dependence (Baker et al.,
2007; Borland et al., 2010; Hyland et al., 2006). Studies
also suggest that these two measures are distinct predic-
tors of addiction (Borland et al., 2010; Lessov et al.,
2004), chronic obstructive pulmonary disease (Guertin
et al., 2015) and lung cancer (Gu et al., 2014), suggesting
the possibility that different genetic factors may contrib-
ute to urgency to smoke and levels of cigarette consump-
tion. In a sample of over 1000 young adults, Haberstick
et al. (2007) found that time to ﬁrst cigarette was the
most informative measure of heritable factors from the
FTND score. Our results complement these ﬁndings by
illustrating that necessity to smoke measured by time to
ﬁrst cigarette after waking at least partly drives the asso-
ciation of the CYP2A6 metabolism metric and nicotine
dependence in young adult daily smokers. Although the
physiologic mechanism underlying this association
remains unknown, slow metabolizer daily smokers likely
have more consistent nicotine levels throughout the day
compared with fast metabolizer daily smokers, which
may contribute to a feeling of greater necessity to smoke
in the morning when nicotine levels are low.
These ﬁndings in young adults should be considered in
the context of the literature about adult smoking.
Previous studies of adults demonstrate that once depen-
dent, slower metabolizers smoke fewer cigarettes to reach
target blood nicotine levels (Benowitz, 2008) (step 3 in
Fig. 3). Although we did not observe an effect of slow
metabolism on risk of smoking more than 20 cigarettes
per day among daily smokers (Table 2, Fig. 2), only 26
percent of these young adults were heavy smokers, and
heaviness of smoking continues to increase throughout
adulthood (NSDUH, 2015). In the entire COGEND sample
ages 25–45 years, a previous analysis demonstrated that
among nicotine dependent smokers, slower metabolism is
associated with decreased cigarette consumption (Bloom
et al., 2012). It is possible that slow metabolism is primar-
ily protective at high levels of cigarette consumption,
which is most evident in older populations of adults.
Overall, these ﬁndings underscore that variation in
CYP2A6 has a variety of effects on smoking behaviors
across stages of development: slow metabolism leads to
increased risk for developing nicotine dependence in
young adult daily smokers through time to ﬁrst cigarette,
but once dependent, slow metabolism is protective
against heaviness of smoking.
Another important consideration is that the fraction of
slow metabolizers in the population of smokers has been
observed to decrease with age, suggesting that slow
metabolizers are more likely to quit smoking (Benowitz,
2008) (step 4 in Fig. 3). In the COGEND dataset, among
current nicotine dependent smokers ages 25–30 years,
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we found that 36 percent (60/166) were slow
metabolizers. However, among current nicotine dependent
smokers over 30 years old, only 28 percent (250/883)
were slow metabolizers (Chi-square, P=0.04), supporting
that proportionally more slow metabolizers have quit by
this time. Furthermore, other studies directly support that
slow nicotine metabolism, measured by CYP2A6 geno-
types or the nicotine metabolite ratio, is associated with
increased cessation rates in both youth (Chenoweth et al.,
2013) and adults enrolled in clinical trials (Chen et al.,
2014; Ray et al., 2009). Taken together, these ﬁndings
suggest that across development, slow metabolizers may
quit smoking more easily. Therefore, the observation that
slow metabolism is associated with increased risk of
nicotine dependence may be most pronounced in samples
of youth when symptoms of dependence are ﬁrst develop-
ing and before cessation attempts occur.
The ﬁndings reported here have limitations. First, this
study focused on individuals of European Ancestry
because themetabolismmetric was optimized for this pop-
ulation (Bloom et al., 2011). Second, the precise timing of
length of transitions between smoking behaviors could
not be examined in these analyses because the smoking
questions did not assess age of onset. Third, the majority
of the COGA participants were from families at high risk
for alcoholism and rates of DSM-IV alcohol dependence
are high in this sample,whichmayaffect the generalizabil-
ityof the ﬁndings. Secondaryanalyses that includeDSM-IV
alcohol dependence as a covariate and replication of the
primary ﬁndings in a community-based recruitment
sample (COGEND), however, support the conclusion that
the ﬁndings are not speciﬁc to a high-risk population.
In summary, using a validated CYP2A6 metabolism
metric, this study demonstrates that slower nicotine
metabolism is associated with an increased risk of nico-
tine dependence in two independent samples of young
adult daily smokers. These ﬁndings add important knowl-
edge about the complex role of CYP2A6 variation across
different developmental stages of smoking behaviors.
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